SCHEMBL456274

SCHEMBL456274

Cc1ncccc1-c1nc2c(S(C)(=O)=O)cccc2cc1C=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP1 P07148 2/20 0.41
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39
CCR1 P32246 1/20 0.37
CCR8 P51685 1/20 0.37
KDM4E B2RXH2 3/20 0.36
MAPT P10636 3/20 0.36
MAPK1 P28482 2/20 0.36
GAA P10253 2/20 0.36
APOBEC3G Q9HC16 2/20 0.36
ATM Q13315 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
CYP2C9 P11712 3/20 0.36
NPSR1 Q6W5P4 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
SLC40A1 Q9NP59 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4178020 0.84 CCR1 (0.39) PTGS1PTGS2CCR1CCR8MAPT
SCHEMBL15363711 0.81 PTGS2 (0.35) FABP1PTGS1PTGS2KDM4EMAPT
SCHEMBL27905393 0.81 TSHR (0.44) PTGS1PTGS2MAPTMAPK1MEN1
SCHEMBL455451 0.81 SCN5A (0.41) FABP1PTGS2CCR1CCR8SLC40A1
SCHEMBL16712443 0.80 DHODH (0.42) FABP1PTGS1PTGS2KDM4EMAPT
SCHEMBL461787 0.80 MEN1 (0.41) FABP1PTGS1PTGS2CCR1CCR8
SCHEMBL456882 0.79 CYP2C9 (0.43) PTGS1PTGS2CYP2C9
SCHEMBL457062 0.78 TGFBR1 (0.38) PTGS1PTGS2CCR1CCR8SLC40A1
SCHEMBL458798 0.76 TSHR (0.41) KDM4EMAPTMAPK1GAAKMT2A
SCHEMBL15363618 0.76 PIK3CD (0.40) FABP1PTGS1PTGS2MAPK1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2614061-B1 QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2015-05-20 EP disclosed
US-9029392-B2 Quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2015-05-12 US disclosed
US-20130296338-A1 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2013-11-07 US disclosed
EP-2614061-A1 QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS UCB Pharma, S.A. (BE) 2013-07-17 EP disclosed
CN-103153996-A Quinoline and quinoxaline derivatives as kinase inhibitors UCB PHARMA SA 2013-06-12 CN disclosed
WO-2012032334-A1 QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296338-A1 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors MAP3K13, MAP4K3, MAP3K3 FABP1 3160/4885PTGS1 997/4885PTGS2 1391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.